Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

GondolaBio: Valuation, Funding & Investors

3160 Porter Dr Palo Alto, California 94304, UShttps://gondolabio.com/Research Platforms

GondolaBio is a biotechnology company focused on discovery and development of biologic therapeutics using platform-driven discovery approaches. The company aims to accelerate identification and optimization of therapeutic candidates by combining experimental discovery methods with integrated data and analytic workflows to shorten target-to-candidate timelines.

Leadership & Board

Current Number of Employees: 109
Current LinkedIn Followers: 6,825

Latest Estimated Valuation

Total Amount Raised: $300M
Total Funding Rounds: 1
Latest Funding Amount: $300M
Latest Funding Round: Investment

Company Momentum Positive

Articles Published on TipRanks1

LinkedIn Trend+1.40% followers

Workforce Trend+0.0% employees

GondolaBio LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.

Employee Trend

GondolaBio had 109 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.

109Latest Employee Count

0(0.00%)Week-Over-Week Change

Social Trend

GondolaBio had 6,825 followers as of October 26, 2026. The number of followers increased by 94 (1.40%) week-over-week.

6,825Latest Followers Count

94(1.40%)Week-Over-Week Change

Funding Round

Funding Date	Funding Round	Amount Raised	Post-Money Valuation
Sep 16, 2024	Investment	$300.00M	―

Similar Companies

A snapshot of private companies similar to GondolaBio, helping you discover and navigate related company profiles.

Kriya Therapeutics Inc

Related News and Analysis

GondolaBio Highlights Patient-Centric Culture in Kidney Disease Focus

GondolaBio Highlights Patient-Centric Culture in Kidney Disease Focus

A LinkedIn post from GondolaBio describes a recent room naming ceremony at the company’s facilities, honoring an individual living with autosomal dominant polycystic kidney disease. The post notes that the

2d ago

GondolaBio Highlights Focus on Maternal Health and Preeclampsia Research

GondolaBio Highlights Focus on Maternal Health and Preeclampsia Research

According to a recent LinkedIn post from GondolaBio, the company’s team participated in the MoMMAs Voices Summit focused on maternal health experiences, including pregnancy, birth complications and infant loss. The

3d ago

Community Engagement Underscores GondolaBio’s Focus on Rare Disease Segment

Community Engagement Underscores GondolaBio’s Focus on Rare Disease Segment

According to a recent LinkedIn post from GondolaBio, the company participated in Connect Alfresco, a British Porphyria Association event for young people living with erythropoietic protoporphyria (EPP) and their families.

1w ago

GondolaBio Highlights Patient-Centric Focus in Charcot-Marie-Tooth Summit Participation

GondolaBio Highlights Patient-Centric Focus in Charcot-Marie-Tooth Summit Participation

According to a recent LinkedIn post from GondolaBio, the company’s team recently participated in the Charcot-Marie-Tooth Association Patient & Research Summit. The event brought together patients, families, advocates and researchers

2w ago

GondolaBio Highlights Engagement With Nano-Rare Disease Community

GondolaBio Highlights Engagement With Nano-Rare Disease Community

According to a recent LinkedIn post from GondolaBio, the company’s team participated in the 2026 Nano-rare Patient Colloquium organized by the n-Lorem Foundation. The post highlights engagement with nano-rare disease

2w ago

GondolaBio Deepens Patient-Centric Engagement in Porphyria Community

GondolaBio Deepens Patient-Centric Engagement in Porphyria Community

According to a recent LinkedIn post from GondolaBio, the company participated in the United Porphyrias Association’s Porphyria Palooza community event. The post highlights a focus on listening to patients and

2w ago

Leadership Recognition Underscores GondolaBio’s Pipeline Execution Focus

Leadership Recognition Underscores GondolaBio’s Pipeline Execution Focus

A LinkedIn post from GondolaBio highlights that Chief Operating Officer Morgan Paull has been recognized as a BioSpace 40 Under 40 honoree. The post notes that Paull has led the

3w ago

GondolaBio Highlights Rare-Disease Focus With EPP And XLP Program

GondolaBio Highlights Rare-Disease Focus With EPP And XLP Program

According to a recent LinkedIn post from GondolaBio, the company is highlighting the clinical burden of erythropoietic protoporphyria, a rare disorder marked by extreme photosensitivity and painful skin reactions. The

1M ago

GondolaBio Highlights Engagement at Rare Disease Drug Development Symposium

GondolaBio Highlights Engagement at Rare Disease Drug Development Symposium

According to a recent LinkedIn post from GondolaBio, the company participated in the Global Genes RARE Drug Development Symposium in Boston, emphasizing engagement with patient advocates, researchers, and industry leaders.

1M ago

GondolaBio Highlights Patient-Focused FD/MAS Research Engagement

GondolaBio Highlights Patient-Focused FD/MAS Research Engagement

According to a recent LinkedIn post from GondolaBio, the company is highlighting the work of Camryn, a leading researcher and advocate focused on Fibrous Dysplasia/McCune-Albright Syndrome (FD/MAS). The post emphasizes

1M ago